Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
ERA 25: Switching from sMRAs to Finerenone
Author(s): Beatriz Fernandez Fernandez Added: 8 months ago
ERA 2025 - Real-world outcomes show switching from treatment with steroidal mineralocorticoid receptor antagonists (sMRAs) to finerenone is a safe option in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D).Dr Beatriz Fernandez Fernandez (Hospital Universitario Fundación Jiménez Dïaz, Madrid, ES) joins us to discuss real-world outcomes from a study investigating the effect of… View more

Cardiovascular Renal Metabolic
ESC HF 25: The PRAISE-HFrEF Study
Author(s): Varun Sundaram Added: 8 months ago
ESC HF 25 - Safety outcomes from PRAISE-HFrEF show that glucagon-like peptide-1 receptor agonism (GLP-1 RA) treatment for heart failure with reduced ejection fraction (HFrEF) and obesity was not associated with increased risk of heart failure hospitalisation or mortality compared to placebo, with greater benefits observed in patients with higher BMI.Dr Varun Sundaram (Case Western Reserve… View more

Cardiovascular Renal Metabolic

Heart Failure
Factor XI Inhibition and AF
Author(s): Bianca Rocca , Hugo ten Cate Added: 10 months ago

Anticoagulation

Electrophysiology & Arrhythmia
Oral P2Y12 Inhibitors and Drug Interactions
Author(s): Elisabetta Bigagli , Jacopo Angelini , Alessandro Mugelli , et al Added: 8 months ago

Anticoagulation

Prevention & Chronic Conditions
Dual-pathway Inhibition versus Aspirin Monotherapy
Author(s): Dirk Sibbing , Michael J Blaha , Rajinder Chawla , et al Added: 1 year ago

Anticoagulation

Prevention & Chronic Conditions
ACC 25: The Phase 3 REVERSE-IT Trial
Author(s): Deepak L Bhatt Added: 10 months ago
ACC 2025 - Phase three results of the use of bentracimab in patients who need urgent ticagrelor reversal show significantly restored platelet function as measured by percent inhibition of P2Y12 Reaction Unit (PRU).Dr Deepak L Bhatt (Mount Sinai Fuster Heart Hospital, New York, US) joins us onsite at ACC 2025 to discuss phase three results from the multi-center, open-label, single-arm REVERSE-IT… View more

Anticoagulation
The Evolving Treatment Landscape for HFpEF in Cardiac Amyloidosis
Author(s): Added: 3 months ago
AHA Scientific Sessions 2025 - Dr Sarah Cuddy (Brigham and Women's Hospital, US) joins us to discuss the role of non-disease modifying treatments including SGLT2 inhibitors, mineralocorticoid receptor antagonists, GLP-1 receptor agonists, and implantable hemodynamic monitors in cardiac amyloidosis, and what this means for managing heart failure in this unique patient population.Interview… View more

Heart Failure
Robert F Storey
Research Area(s) / Expertise: Job title: Professor and Honorary Consultant in Cardiology
Prof Robert Storey is Academic Director and an honorary Consultant Cardiologist for the Cardiology and Cardiothoracic Surgery Directorate, Sheffield Teaching Hospitals NHS Foundation Trust. He is Professor of Cardiology at the University of Sheffield, UK, where he has headed a platelet research group since 2002 within the Department of Cardiovascular Science. He has a special interest in the… View more
Research Area(s) / Expertise: Job title: Professor
Professor Keith AA Fox is Duke of Edinburgh Professor of Cardiology at the University of Edinburgh. Previous posts included Assistant Professor of Internal Medicine and Cardiology at Washington University School of Medicine, St Louis, USA; Senior Lecturer in Cardiology and Honorary Consultant Cardiologist at the University of Wales College of Medicine, Cardiff; Head of Division of Medical and… View more
Research Area(s) / Expertise: